<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150394</url>
  </required_header>
  <id_info>
    <org_study_id>VALACT-2017-01</org_study_id>
    <nct_id>NCT03150394</nct_id>
  </id_info>
  <brief_title>Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Luis Fernandez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori is a Gram-negative bacterium with a helical bacillus shape that it's able
      to penetrate and colonize the stomach mucosal lining by infecting it.

      The eradication treatment of H. pylori is supported by numerous consensus groups worldwide
      and it is generally safe and well tolerated. Standard treatment is based on multiple drug
      regimens. However, its effectiveness has been increasingly compromised due to the emergence
      of resistant strains, as well as poor adherence to treatment. Therefore, it's proposed a
      randomized, double-blind, placebo-controlled study whose aims are:

        1. Determine whether the combination of two probiotic strains of L reuteri (Gastrus) will
           improve gastrointestinal symptoms when associated with four-way therapy (of any type).

        2. Prove whether supplementation with Gastrus (food supplement) versus Placebo is able to
           reduce the gastrointestinal adverse effects of quadruple eradication therapy.

      They will be determined by the GSRS gastrointestinal symptom scale in routine clinical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global score of gastrointestinal symptoms assessed according the GSRS scale</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score obtained from each individual gastrointestinal symptom evaluated according the GSRS scale. Percentage of patients completing treatment</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Treatment of quadruple eradication therapy with GASTRUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment of quadruple eradication therapy with PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>GASTRUS</intervention_name>
    <description>Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment</description>
    <arm_group_label>Treatment of quadruple eradication therapy with GASTRUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment</description>
    <arm_group_label>Treatment of quadruple eradication therapy with PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients attended at the clinic visit who present a positive diagnosis of H pylori
             infection using different diagnostic techniques (C13 breath test, histology, urease
             and / or H pylori antigen in stools).

          -  Age between 18 and 65 years

        Exclusion Criteria:

          -  Patients taking other probiotics 4 weeks prior to study start.

          -  Patients who have previously received eradicating therapy.

          -  Patients who are treated with NSAIDs, aspirin or other anti-inflammatory drugs either
             on an occasional basis (one week prior to the study) or on a chronic basis (3 weeks
             prior to inclusion).

          -  Patients who have used oral antibiotics two weeks prior to inclusion.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Fernandez Dr. Jesus Barrio</last_name>
    <role>Study Director</role>
    <affiliation>Managers study</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Fernandez, PhD</last_name>
    <phone>+34607537815</phone>
    <email>luisfernsal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesus Barrio, PhD</last_name>
    <email>jbarrioa95@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fernandez, PhD</last_name>
      <phone>+34607537815</phone>
      <email>luisfernsal@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Río Hortega.</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Barrio, PhD</last_name>
      <email>jbarrioa95@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Dr. Luis Fernandez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

